Update on the optimal use of voriconazole for invasive fungal infections

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.

Original languageEnglish (US)
Pages (from-to)43-53
Number of pages11
JournalInfection and Drug Resistance
Volume4
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Azoles
Triazoles
Aspergillosis
Clinical Pharmacology
Drug Monitoring
Drug Interactions
Biological Availability
Serum
Pharmaceutical Preparations
Voriconazole
Invasive Fungal Infections

Keywords

  • Aspergillosis
  • Candidiasis
  • Therapeutic drug monitoring
  • Voriconazole

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology

Cite this

Update on the optimal use of voriconazole for invasive fungal infections. / Lat, Asma; Thompson, George Richard.

In: Infection and Drug Resistance, Vol. 4, No. 1, 2011, p. 43-53.

Research output: Contribution to journalArticle

@article{d3e8bb0ce3374617a50d7829bf87710a,
title = "Update on the optimal use of voriconazole for invasive fungal infections",
abstract = "Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.",
keywords = "Aspergillosis, Candidiasis, Therapeutic drug monitoring, Voriconazole",
author = "Asma Lat and Thompson, {George Richard}",
year = "2011",
doi = "10.2147/IDR.S12714",
language = "English (US)",
volume = "4",
pages = "43--53",
journal = "Infection and Drug Resistance",
issn = "1178-6973",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Update on the optimal use of voriconazole for invasive fungal infections

AU - Lat, Asma

AU - Thompson, George Richard

PY - 2011

Y1 - 2011

N2 - Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.

AB - Voriconazole is an extended-spectrum triazole with excellent bioavailability that has now become the treatment of choice for aspergillosis. It has a unique side effect profile compared with other azoles, as well as a number of clinically important drug-drug interactions. These factors, along with a correlation between increased serum levels and improved outcomes, have prompted an interest in therapeutic drug monitoring of this agent. The pharmacology and clinical outcomes data of voriconazole are presented in this review.

KW - Aspergillosis

KW - Candidiasis

KW - Therapeutic drug monitoring

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=79952675005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952675005&partnerID=8YFLogxK

U2 - 10.2147/IDR.S12714

DO - 10.2147/IDR.S12714

M3 - Article

C2 - 21694908

AN - SCOPUS:79952675005

VL - 4

SP - 43

EP - 53

JO - Infection and Drug Resistance

JF - Infection and Drug Resistance

SN - 1178-6973

IS - 1

ER -